Bronhoval 30mg 2p x 20 tablets — Made in Germany — Free Delivery

Indications

Secretolytic therapy for acute and chronic bronchopulmonary diseases associated with impaired bronchial secretion and weakening of mucus movement.

Application

Tablets. unless otherwise prescribed, the recommended dose of Bronchoval Tablets is as follows:

children aged 6 to 12 years: as a rule, the dose is ½ tablet 2-3 times a day (equivalent to 30-45 mg ambroxol hydrochloride per day);

adults and children over 12 years of age: as a rule, the dose is 1 tablet 3 times a day for the first 2-3 days (equivalent to 90 mg ambroxol hydrochloride per day). Continue treatment with 1 tablet 2 times a day (equivalent to 60 mg ambroxol hydrochloride per day).

If necessary, the therapeutic effect for adults and children over the age of 12 years can be enhanced by the use of 2 tablets 2 times a day (equivalent to 120 mg of ambroxol hydrochloride per day).

The tablets must be swallowed whole with sufficient liquid (eg water, tea or fruit juice) after a meal.

The preparation should not be used for longer than 4-5 days without consulting a doctor.

Syrup. Unless otherwise prescribed, the recommended dose of Bronchoval Syrup is as follows:

children under 2 years of age: 2.5 ml (½ scoop) 2 times a day (equivalent to 15 mg ambroxol hydrochloride per day);

children aged 2-6 years: 2.5 ml (½ scoop) 3 times a day (equivalent to 22.5 mg ambroxol hydrochloride per day);

children aged 6-12 years: 5 ml (1 scoop) 2-3 times a day (equivalent to 30-45 mg ambroxol hydrochloride per day);

adults and children over 12 years of age: 10 ml (2 scoops) 3 times a day (equivalent to 90 mg ambroxol hydrochloride per day) for the first 2-3 days and then 10 ml (2 scoops) 2 times a day (equivalent to 60 mg ambroxol hydrochloride per day).

If necessary, the therapeutic effect for adults and children over the age of 12 years can be enhanced by increasing the dose to 20 ml 2 times a day (equivalent to 120 mg of ambroxol hydrochloride per day).

The preparation can be used regardless of the meal.

In general, there are no restrictions on the duration of use, but long-term therapy should be carried out under medical supervision. The preparation should not be used for longer than 4-5 days without consulting a doctor.

Contraindications

The preparation should not be used in patients with known hypersensitivity to ambroxol hydrochloride or other components of the preparation. in case of rare hereditary conditions due to which incompatibility with the excipient of the preparation is possible (see special instructions), the use of the preparation is contraindicated.

Side effects

General disorders: hypersensitivity reactions (skin rash, mucosal reactions, angioedema, dyspnea, itching and other allergic reactions), urticaria, fever, anaphylactic reactions, including anaphylactic shock.

From the skin and subcutaneous tissue: erythema, severe skin lesions: Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome).

From the digestive system: diarrhea, gastrointestinal complaints (eg nausea, vomiting, dyspepsia, abdominal pain), dry mouth, heartburn, constipation, salivation.

From the respiratory system: rhinorrhea, dryness of the respiratory tract.

From the urinary system: dysuria.

special instructions

There have been several reports of severe skin lesions (Stevens-Johnson syndrome and toxic epidermal necrolysis (Lyell's syndrome)) associated with the use of expectorants such as ambroxol hydrochloride. they can be mainly explained by the severity of the underlying disease in patients or by simultaneous use with another preparation. therefore, if new lesions of the skin or mucous membrane appear, you should immediately seek medical help and stop treatment with the preparation.

Bronchoval tablets contain lactose, so patients with rare hereditary problems of galactose intolerance, lactase deficiency or glucose-galactose malabsorption syndrome should not use this preparation. Bronchoval syrup contains sorbitol solution, so people with rare hereditary fructose intolerance should not take this medicine. 1 scoop (5 ml) contains 1.75 g of sorbitol (which is a source of 0.44 g of fructose), which is equivalent to ≈0.15 XE. Sorbitol may have a mild laxative effect. Bronchoval syrup does not contain alcohol.

Since ambroxol can increase mucus secretion, the preparation must be used with caution in violation of bronchial motility and increased mucus secretion (for example, in such a rare disease as primary ciliary dyskinesia).

The preparation should be used with caution in patients with impaired renal function or severe liver disease (namely, the interval between doses should be increased or the dose should be reduced).

In patients with severe renal insufficiency, the accumulation of metabolites formed in the liver is expected.

Use during pregnancy and lactation. Pregnancy. Ambroxol hydrochloride crosses the placental barrier. Animal studies have not shown direct or indirect harmful effects on pregnancy, embryo/fetal development, childbirth or postnatal development.

As a result of studies of the use of the preparation after the 28th week of pregnancy, not a single harmful effect on the fetus was revealed.

However, it is necessary to observe the usual measures regarding the use of medicines during pregnancy. The preparation is not recommended for use especially in the first trimester of pregnancy.

Lactation. Ambroxol hydrochloride passes into breast milk. Although no adverse effects on infants are expected, the preparation is not recommended for use during breastfeeding.

Children. Bronchoval syrup can be used in pediatric practice; in children under the age of 2 years, use as prescribed by a doctor. Bronchoval tablets are used in children over 6 years of age who cannot tolerate Bronchoval syrup.

The ability to influence the reaction rate when driving vehicles or working with other mechanisms. There is no data on the effect on the reaction rate when driving vehicles or working with other mechanisms.

Interactions

The simultaneous use of ambroxol hydrochloride and cough suppressants can lead to excessive accumulation of mucus due to suppression of the cough reflex. therefore, such a combination is possible only after a thorough assessment by the doctor of the ratio of expected benefits and possible risks of use.

Overdose

Symptoms. Ambroxol was well tolerated after parenteral administration at doses up to 15 mg/kg/day and after oral administration up to 25 mg/kg/day. after an overdose of ambroxol, no severe signs of intoxication were observed. cases of restlessness and diarrhea were reported, which quickly resolved.

Excessive overdose can lead to hypersalivation, urge to vomit, vomiting and a decrease in blood pressure.

Treatment. Emergency measures such as inducing vomiting and gastric lavage are generally not indicated and should be used in case of acute intoxication. Symptomatic treatment is recommended.

Storage conditions

At a temperature not higher than 25 ° C; after opening the vial, the syrup should be stored for 12 months at a temperature not exceeding 25 ° C. Keep out of the reach of children.